Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH

Ryan D. Welch, Cyrielle Billon, McKenna Losby, Gonzalo Bedia‐diaz, Yuanying Fang, Amer Avdagic, Bahaa Elgendy, Thomas P. Burris, Kristine Griffett

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Non‐alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV‐ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptors and their biology has promoted the development of synthetic ligands. The possibility of targeting these receptors to treat NAFLD is promising, as several compounds includ-ing Cilofexor, thiazolidinediones, and Saroglitazar are currently undergoing clinical trials. This review focuses on the latest development of the pharmacology of these metabolic nuclear receptors and how they may be utilized to treat NAFLD and subsequent comorbidities.

Original languageEnglish
Article number238
Issue number3
StatePublished - Mar 2022


  • Fibrosis
  • Glucose metabolism
  • Inflammation
  • Insulin sensitivity
  • Lipogenesis
  • Metabolism
  • Non‐alcoholic fatty liver disease
  • Non‐alcoholic steatohepatitis
  • Nuclear receptors
  • Oxidative stress
  • Therapeutics


Dive into the research topics of 'Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH'. Together they form a unique fingerprint.

Cite this